Uniqure NV Corporate Call Transcript
Good morning, everyone, and welcome to uniQure's Virtual Investor Event. I'm Maria Cantor, Chief Corporate Affairs Officer at uniQure. We appreciate you taking time to be with us today as we feature our pipeline program in temporal lobe epilepsy and highlight our recent advances in manufacturing technology.
Before we get started, please note that we'll be making a number of forward-looking statements this morning. We suggest to take a moment to review this slide, which contains our forward-looking statements. These statements involve risks and uncertainties, many of which are beyond uniQure's control and actual results could differ materially from these statements.
For a detailed description of these risks and uncertainties, we encourage you to review the company's most recent Form 10-Q filed with the Securities and Exchange Commission as well as the company's other SEC filings.
Our program will begin this morning with an introduction by Matt Kapusta, uniQure's CEO, on the company's history of leadership in gene
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |